Date: 2012-12-14
Type of information: Grant
Company: AxoGlia Therapeutics (Luxembourg)
Investors: The Michael J. Fox Foundation - MJFF (USA)
Amount: undisclosed
Funding type: grant
Planned used: The Michael J. Fox Foundation grant will be used to study the “Modulation of the CD40/CD40-Ligand euroinflammatory pathway in Parkinson’s preclinical models.”
Others: AxoGlia Therapeutics SA, a biopharmaceutical company which drives the development of innovative neural stem/progenitor cell differentiation and neuroprotective therapeutics, has been awarded a Rapid Response Innovative Award from The Michael J. Fox Foundation, for a project that is performed in collaboration with the Luxembourg Centre for Systems Biomedicine (LCSB). The Michael J. Fox Foundation grant will be used to study the “Modulation of the CD40/CD40-Ligand euroinflammatory pathway in Parkinson’s preclinical models.”
Dr. Djalil Coowar, AxoGlia’s CSO and Principal Investigator, and his colleague at LSCB, Dr. Manuel Buttini, expect that by blocking neuroinflammation through the disruption of the CD40-CD40L pathway, a neuroprotective, disease-modifying effect will be achieved. Modulating neuroinflammation in Parkinson’s disease could prove to be of therapeutic benefit and we are grateful to The Michael J. Fox Foundation for their support to our innovative strategies that identify neurorestorative and neuroprotective drug candidates,” said AxoGlia’s CEO Jean-Paul Scheuren.
Based in Luxembourg, AxoGlia is a pioneer in the development of small chemical entities having dual anti-neurodegenerative and anti-inflammatory capacities. These molecules act on two levels: the regeneration of nervous cells by influencing the cell fate / maturation of cellular precursors and modulating the activation of microglial cells.
Therapeutic area: Neurodegenerative diseases
